Healthcare companies invest heavily in new medicines and drugs. Pharmaceutical companies alone spend on average 17% of revenues on R&D, making it one of the biggest costs in this area.
Patent linkage is a complex issue as it merges the protection of IP governed by IP laws with the remit of drug regulators, which varies by country. Pharmaceutical companies need to know which jurisdiction adopts a patent linkage regime when adopting an enforcement strategy or seeking regulatory approval for a new product. The Guide is timely particularly given the growth in the development of biologics and biosimilars.
Covering over 35 key jurisdictions, the Global Guide to Patent Linkage is a comprehensive resource, produced in partnership with the International Association of Pharmaceutical Manufacturers (AIPM), that explores which legal regimes adopt patent linkage doctrines and what enforcement options are open to drug patent rights holders to protect their assets.